| Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial BR Haight, SM Learned, CM Laffont, PJ Fudala, Y Zhao, AS Garofalo, ... The Lancet 393 (10173), 778-790, 2019 | 251 | 2019 |
| Economic burden of long‐term complications of deep vein thrombosis after total hip replacement surgery in the United States JA Caprini, MF Botteman, JM Stephens, V Nadipelli, MM Ewing, S Brandt, ... Value in Health 6 (1), 59-74, 2003 | 232 | 2003 |
| Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder NA Ronquest, TM Willson, LB Montejano, VR Nadipelli, BA Wollschlaeger Substance abuse and rehabilitation, 59-78, 2018 | 94 | 2018 |
| Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system JA Boscarino, HL Kirchner, JM Pitcavage, VR Nadipelli, NA Ronquest, ... Substance abuse and rehabilitation, 131-141, 2016 | 80 | 2016 |
| Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and … MF Botteman, J Caprini, JM Stephens, V Nadipelli, CF Bell, CL Pashos, ... Clinical therapeutics 24 (11), 1960-1986, 2002 | 73 | 2002 |
| RB-US-13-0001 Study Investigators.(2019). Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind … BR Haight, SM Learned, CM Laffont, PJ Fudala, Y Zhao, AS Garofalo, ... Lancet 393 (10173), 778-790, 0 | 51 | |
| Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study W Ling, VR Nadipelli, CT Solem, NA Ronquest, YC Yeh, SM Learned, ... Journal of Substance Abuse Treatment 110, 1-8, 2020 | 49 | 2020 |
| Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study W Ling, VR Nadipelli, AP Aldridge, NA Ronquest, CT Solem, H Chilcoat, ... Journal of addiction medicine 14 (5), e233-e240, 2020 | 43 | 2020 |
| Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in … PK Schädlich, M Kentsch, M Weber, W Kämmerer, JG Brecht, V Nadipelli, ... Pharmacoeconomics 24, 571-591, 2006 | 41 | 2006 |
| Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study W Ling, VR Nadipelli, CT Solem, NA Ronquest, YC Yeh, SM Learned, ... Journal of addiction medicine 13 (6), 442-449, 2019 | 36 | 2019 |
| Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis AC Andorn, BR Haight, S Shinde, PJ Fudala, Y Zhao, C Heidbreder, ... Journal of clinical psychopharmacology 40 (3), 231-239, 2020 | 34 | 2020 |
| Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes H Un, J Volpicelli The American journal of managed care 23 (6), e172-e179, 2017 | 31 | 2017 |
| Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled … JJ Isitt, VR Nadipelli, A Kouassi, M Fava, C Heidbreder Schizophrenia research 174 (1-3), 126-131, 2016 | 29 | 2016 |
| Cost‐effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in spain MJC Nuijten, FA Villar, J Kosa, V Nadipelli, C Rubio‐Terres, C Suarez Value in Health 6 (2), 126-136, 2003 | 23 | 2003 |
| Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse BA Wollschlaeger, TM Willson, LB Montejano, NA Ronquest, VR Nadipelli Journal of Opioid Management 13 (4), 207-220, 2017 | 22 | 2017 |
| Cost-effectiveness of enoxaparin as thromboprophylaxis in acutelly ill medical patients from the Italian NHS perspective. MJ Nuijten, P Berto, J Kosa, V Nadipelli, C Cimminiello, A Spreafico Recenti progressi in medicina 93 (2), 80-91, 2002 | 22 | 2002 |
| Remission from chronic opioid use—Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics W Ling, VR Nadipelli, NA Ronquest, VA Albright, AP Aldridge, ... Contemporary Clinical Trials 76, 93-103, 2019 | 19 | 2019 |
| Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the treatment effectiveness assessment W Ling, VR Nadipelli, CT Solem, D Farabee, NA Ronquest, B Perrochet, ... Substance Abuse and Rehabilitation, 13-21, 2019 | 16 | 2019 |
| Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome M Brosa, C Rubio-Terrés, I Farr, V Nadipelli, J Froufe Pharmacoeconomics 20, 979-987, 2002 | 13 | 2002 |
| Análisis costo-efectividad de enoxaparina en la profilaxis de la enfermedad tromboembólica venosa en pacientes sometidos a cirugía mayor ortopédica B Riestra, C Rubio-Terrés, V Nadipelli, AC Collado, FM Brotons Farmacia Hospitalaria 27 (4), 2003 | 11 | 2003 |
Chris PashosGenesis Research在 genesisrg.com 的电子邮件经过验证
